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a b s t r a c t
Coronaviruses (CoVs) are positive-stranded RNA viruses with potential as immunization vectors,
expressing high levels of heterologous genes and eliciting both secretory and systemic immune
responses. Nevertheless, its high recombination rate may result in the loss of the full-length foreign
gene, limiting their use as vectors. Transmissible gastroenteritis virus (TGEV) was engineered to express
porcine reproductive and respiratory syndrome virus (PRRSV) small protein domains, as a strategy to
improve heterologous gene stability. After serial passage in tissue cultures, stable expression of small
PRRSV protein antigenic domains was achieved. Therefore, size reduction of the heterologous genes
inserted in CoV-derived vectors led to the stable expression of antigenic domains. Immunization of
piglets with these TGEV vectors led to partial protection against a challenge with a virulent PRRSV strain,
as immunized animals showed reduced clinical signs and lung damage. Further improvement of
TGEV-derived vectors will require the engineering of vectors with decreased recombination rate.
& 2014 Elsevier Inc. All rights reserved.
Introduction
The order Nidovirales comprises enveloped single-stranded,
positive-sense RNA viruses. The Nidovirales order includes the
Coronaviridae family that contains viruses with the largest known
RNA genome, of around 30 Kb (Enjuanes et al., 2008). Coronavirus
(CoVs) infect a wide range of mammalian and avian species.
The development of efﬁcient CoV reverse genetics systems
(Almazan et al., 2006, 2013, 2000, 2014; Casais et al., 2001; Thiel
et al., 2001; Yount et al., 2003, 2002) makes them promising
expression vectors, with several advantages over other viral
expression systems. CoVs replicate in the cytoplasm without a
DNA intermediary, making integration of the virus genome into
the host cell chromosome unlikely (Lai and Cavanagh, 1997). In
addition, these viruses have the largest RNA virus genome and, in
principle, have room for the insertion of large foreign genes
(Enjuanes et al., 2005; Masters, 1999). As CoVs in general infect
both respiratory and enteric mucosal surfaces, they may be used to
target the antigen to these areas, stimulating the mucosal immune
system to induce a pleiotropic secretory immune response, includ-
ing lactogenic immunity (Sola et al., 2003). In fact, it has been
described that a pleiotropic secretory immune response is best
induced by the stimulation of gut associated lymphoid tissues
(Saif, 1996). Moreover, the tropism of CoVs may be engineered by
modifying the spike (S) gene (Casais et al., 2003; Sanchez et al.,
1999), and non-pathogenic CoV strains infecting most species of
interest (human, porcine, bovine, canine, feline, and avian) are
available and therefore are suitable to develop safe virus vectors
(Cavanagh et al., 2007; Ortego et al., 2002).
In fact, several studies have reported the construction of CoV-
derived viral vectors expressing high levels of heterologous
proteins, including reporter and viral proteins (Bentley et al.,
2013; Ribes et al., 2011; Shen et al., 2009, 2003). Foreign gene
expression levels can be regulated by the use of different
transcription-regulating sequences (TRSs) ranging from intermedi-
ate to high gene expression levels (Alonso et al., 2002a). In
addition, our group has recently identiﬁed an optimized
transcription-regulating motif, enhancing by 5-fold the mRNA
levels of a viral gene, which can be used in expression vectors
based in CoV genomes (Mateos-Gomez et al., 2011). Additionally, a
combination of these TRSs could be used to drive the expression of
two or three heterologous genes from just one infectious cDNA
(i.e., dicistronic or tricistronic vectors).
Genetic stability of a heterologous gene within the viral vector
is essential for its development as a live immunization vector. In
general, the stability of heterologous genes is high for DNA viruses
and negative RNA viruses, in which the low level of recombination
contributes to the maintenance of the inserted foreign genes
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(Bukreyev et al., 2006) In contrast, positive RNA viruses are highly
prone to recombination, both homologous and non-homologous
(Alejska et al., 2005; Figlerowicz et al., 2003) leading to the loss of
the inserted genes and avoiding their expression over a long time
period. CoVs are positive RNA genomes with high recombination
frequency (Denison et al., 2011; Lai, 1996; Sanchez et al., 1992).
Genetic instability leading to the loss of heterologous genes has
been frequently reported in CoV-derived vectors, both in vitro
(Bentley et al., 2013; Cruz et al., 2010; Sola et al., 2003) and in vivo
(Bentley et al., 2013).
In view of the frequent instability of CoV-based vectors expres-
sing proteins of large size, we explored whether the reduction of
heterologous gene size was a useful strategy to increase insert
stability, by reducing the probability of the presence of toxic
domains in the inserted gene or protein. In fact, the expression
of small protein domains is a common strategy used to reduce
toxicity when toxic proteins are expressed in bacteria (Edwards
et al., 2000; Samuelson, 2011).
TGEV infects the enteric and respiratory tissues of newborn
piglets resulting in a mortality of nearly 100% (Saif and Wesley,
1992). Interestingly, some non-enteric TGEV variants with altera-
tions in the S protein have a tropism restricted to the respiratory
tract, and show attenuated phenotype (Sanchez et al., 1999).
TGEV-derived vectors have been successfully engineered for the
expression of green ﬂuorescent protein (GFP). The GFP gene was
expressed by replacing the non-essential genes 3a and 3b, leading
to very stable (420 passages in tissue culture) high expression
levels of the heterologous protein (50 μg/106cells) (Sola et al.,
2003). Recombinant TGEV (rTGEV) vectors have been engineered
for dicistronic expression of heterologous genes, such as porcine
reproductive and respiratory syndrome virus (PRRSV) GP5 and M
proteins (Cruz et al., 2010), or rotavirus VP2 and VP6, in which
formation of rotavirus virus like particles (VLPs) in the cytoplasm
of rTGEV infected cells was observed (Enjuanes et al., 2007).
TGEV has been previously used as an immunization vector to
confer partial protection against PRRSV infection (Cruz et al.,
2010). In addition, an engineered rTGEV in which the tropism
was modiﬁed replacing the S protein by the homologous one from
mouse hepatitis virus (MHV) was used to confer protection against
rotavirus infections (Ribes et al., 2011). The engineered rTGEV
expressing rotavirus VP7 protein was then evaluated in the mouse
model. The recombinant virus triggered a humoral response via
systemic (serum IgG and IgA) and mucosal (intestinal IgA) anti-
bodies. In addition, partial protection against rotavirus-induced
diarrhea was observed in 62% of the challenged animals.
Porcine reproductive and respiratory syndrome (PRRS) is the
most important infectious disease affecting swineherds world-
wide. It is characterized by reproductive failure in sows, as well as
severe pneumonia in piglets (Lunney et al., 2010). The causative
agent of PRRS is PRRS virus (PRRSV) that is included in Arterivir-
idae family, in the order Nidovirales. PRRSV is an enveloped, single-
stranded positive sense RNA virus of approximately 15 Kb in
length that contains 9 open reading frames (ORFs). ORF1a and
ORF1b encode the replicase non-structural proteins, while ORFs
2 to 7 encode structural proteins: the small envelope protein (E),
the membrane protein (M), nucleocapsid protein (N) and the
glycoproteins GP2a, GP3, GP4, GP5, and the recently identiﬁed
protein 5a (Dokland, 2010; Firth et al., 2011; Johnson et al., 2011).
Currently, PRRS causes huge economic losses in the swine indus-
try, but commercially available vaccines are only partially effective
(Charerntantanakul, 2012).
PRRSV infection induces a weak innate immune response,
probably contributing to the reduced and delayed subsequent
humoral and cellular immune responses, and also to virus persis-
tence (Kimman et al., 2009). This is probably due to the limited
interferon alpha (IFN-α) elicited by PRRSV (Albina et al., 1998;
Calzada-Nova et al., 2010). The knowledge on PRRSV correlates of
protection is limited. Neutralizing antibodies against PRRSV are
mainly directed to GP5 protein (Kim and Yoon, 2008; Ostrowski
et al., 2002), although neutralizing antibodies recognizing GP3 and
GP4 have also been described following PRRSV infection (Costers
et al., 2010; Oleksiewicz et al., 2002; Vanhee et al., 2011). PRRSV M
protein is a potent inducer of T-cell proliferation in piglets infected
with PRRSV, and may also play a role in protection (Bautista et al.,
1999; Jeong et al., 2010).
Current vaccines against PRRSV have a limited efﬁcacy. Best
results have been obtained using modiﬁed live vaccines, although
they have several problems such as incomplete protection, virus
shedding and possible reversion to virulence (Charerntantanakul,
2012). Vector-based vaccines could represent an advantage to
stimulate both humoral and cell immune responses against PRRSV
(Cruz et al., 2010). Given the potential of CoV-derived vectors, and
the requirement of more efﬁcient vaccines against PRRSV, the
work presented here is focused on the use of TGEV as a vector for
the expression of PRRSV antigenic combinations. The expression of
PRRSV small domains containing the epitopes relevant for protec-
tion would lead to a signiﬁcant increase in vector stability.
Previous work from our laboratory has shown that rTGEVs co-
expressing full-length PRRSV GP5 (wild type or modiﬁed) and M
proteins induced partial protection against PRRSV (Cruz et al.,
2010). The modest results obtained may be due to the instability of
GP5 protein in the rTGEV system, resulting in a signiﬁcant loss of
GP5 expression in 8–10 passages in tissue culture. Expression of
full-length PRRSV GP3 or GP4 proteins was also toxic for rTGEV
leading to the loss of the heterologous gene sequence (M. Becares,
S. Zuñiga and L. Enjuanes, unpublished results). In this work the
stability of the expression of small domains of PRRSV GP3, GP4 and
GP5, previously described as potentially relevant in the induction
of protection against PRRSV has been studied, in comparison with
the expression of full-length proteins, using rTGEV vectors. Our
results showed that reduction of the heterologous genes size
inserted in the CoV-derived vector is a promising strategy to
achieve stable expression. Additionally, as PRRSV M protein was
stable in rTGEV, several antigenic structures were engineered
using this protein as scaffold for the expression of small antigenic
domains, resulting in high stability. Furthermore, immunization of
piglets with these live attenuated rTGEV vectors partially pro-
tected against PRRSV, with reduction of clinical signs and lung
damage as well as a faster viremia decrease.
Results
PRRSV M protein is stably expressed by rTGEV
PRRSV M protein is a long non-glycosilated membrane protein
of around 170 amino acids, which is the most highly conserved
structural protein of PRRSV (Meng et al., 1995) and has been
involved in the induction of T-cell response against PRRSV
(Bautista et al., 1999). A rTGEV vector expressing PRRSV M protein
was generated encoding PRRSV M gene in the location previously
occupied by non-essential genes 3a and 3b. PRRSV M gene
expression was driven by the transcription-regulating sequence
of gene 3a (TRS3a) (Fig. 1A).
A rTGEV-S7.1-TRS3a-M was recovered, with a titer of 108 pfu/ml,
as expected for rTGEV viruses. In order to test the stability of
PRRSV M protein expressed by this vector, cloned viruses were
serially passaged in tissue culture and the maintenance of
the heterologous gene was evaluated at different passages by the
analysis of plaque-puriﬁed viral clones. The presence of the
heterologous sequence in the viral genome was evaluated by
RT-PCR, using speciﬁc primers ﬂanking the insertion region.
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After 8 and 16 serial passages of the rTGEV-S7.1-TRS3a-M, all the
isolated viral clones still contained M gene sequence (Fig. 1B), with
the expected size and sequence as revealed by PCR product
sequencing. In addition, all the isolated clones expressed M
protein mRNA (Fig. 1B), conﬁrming M gene stability in rTGEV
system.
Moreover, M protein expression was analyzed by immunoﬂuor-
escence in ST cells infected at moi 0.5. M protein was expressed in
96% of the infected cells (Fig. 1C), with expression levels remaining
constant through the passages (data not shown). Altogether, these
results indicated that expression of PRRSV M protein in rTGEV was
fully stable.
Expression of small domains of PRRSV GP5 protein using rTGEV
Netralizing antibodies recognizing GP5 are considered the most
relevant for protection, with the epitope responsible for the
neutralization located in the ectodomain of GP5 protein (Kim
and Yoon, 2008; Ostrowski et al., 2002). Previous studies from our
group indicated that the partial protection observed after immu-
nization with rTGEVs expressing full length GP5 protein, both wild
type or glycosylation mutants, was probably due to the toxicity of
this protein in rTGEV system, leading to heterologous gene loss
with passages (Cruz et al., 2010). As a consequence, we decided to
evaluate the expression of small domains containing epitopes
potentially relevant in protection, as the reduction of potential
toxic domains could increase vector stability.
In a ﬁrst approach, a rTGEV co-expressing GP5 ectodomain
(GP5ecto) and M protein was engineered. GP5ecto transcription
was driven by the TRS3a, and that of M protein by an optimized
TRS partially derived from gene N TRS (TRS22N) (Alonso et al.,
2002a). M protein was included in the rTGEV construct because it
was fully stable and we previously observed that it increased GP5
stability, probably by forming the heterodimer observed in the
native virus (Cruz et al., 2010). In fact, we postulate that the
expressed GP5 domains and M protein could form a heterodimer
similar to the one observed in the virus, what may be important
for its immunogenicity. GP5ecto consisted in the 68 most
N-terminal amino acids of the Olot91 GP5 protein, which accord-
ing to bioinformatics predictions cover the ectodomain of the
protein. This domain included the protein motifs relevant in
protection, such as the immunodominant epitope and the epitope
Fig. 1. Expression of PRRSV M protein by rTGEV-derived vectors. (A) Schematic structure of the rTGEV cDNA encoding the PRRSV M gene. The numbers and letters inside the
rectangles indicate the viral genes. TRS, transcription-regulating sequence. (B) RT-PCR analysis of ten clones from plaque-puriﬁed passage 16 rTGEV-S7.1-TRS3a-M virus.
Genomic RNA (gRNA) and subgenomic mRNA (mRNA) encoding PRRSV M protein were detected. The arrow indicates the expected size of the corresponding PCR product.
Numbers on the left indicate the molecular weight markers (Mw) size in base pairs. (C) Immunoﬂuorescence analysis of ST cells infected with the passage 16 rTGEV-S7.1-
TRS3a-M at 8 hpi. A polyclonal antibody speciﬁc for TGEV and a secondary antibody staining red were used to identify virus-infected cells. Expression of PRRSV M protein was
detected with a monoclonal antibody and a secondary antibody staining green.
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critical in neutralization as well as the glycosylation sites (Fig. 2A).
To allow GP5ecto protein detection, a hemaglutinin (HA) tag was
fused to GP5 protein domain (Fig. 2A). This tag is small (9 amino
acids) and was previously used for CoV protein tagging, without
showing any toxicity (Alvarez et al., 2010). rTGEV-S7.1-TRS3a-
GP5ecto-TRS22N-M was recovered with titers similar to those of
wt virus. The stability of GP5ecto domain with virus passages was
analyzed by RT-PCR analysis of isolated clones. After 8 passages in
tissue culture, 80% of the isolated clones contained the GP5ecto
sequence (Fig. 2B) and expressed the corresponding mRNA (data
not shown), representing a modest increase of stability compared
with GP5 full-length (60% stable) (Fig. 2B). Unfortunately, in both
cases, the heterologous GP5 sequences were lost at passage 16
(data not shown), indicating that GP5ecto long-term stability did
not represent a sufﬁcient improvement as compared to full-length
GP5. Similar conclusions were extracted from immunoﬂuores-
cence analysis of protein expression (data not shown).
In a second step, an additional reduction in GP5 size was
designed, by eliminating the predicted signal peptide of GP5,
whose cleavage is controversial (Thaa et al., 2013; Wissink et al.,
2003). The resulting 34 amino acid fragment of GP5 protein
(GP5fr) was inserted in rTGEV, leading to rTGEV-S7.1-TRS3a-
GP5fr-TRS22N-M virus. This small domain contained the GP5
epitope critical in neutralization, glycosylation sites and the
cysteine residue involved in the GP5-M heterodimer formation.
For GP5fr detection a FLAG tag was fused at the carboxi-terminus
(Fig. 2A). This FLAG tag has been successfully used in CoV protein
tagging (Alvarez et al., 2010). The additional size reduction of the
GP5 fragment cloned in rTGEV led to an improvement in hetero-
logous gene stability after 8 passages in tissue culture, with 90% of
the independent clones containing GP5fr sequence (Fig. 2B) and
expressing GP5fr mRNA (data not shown). Moreover, long-term
stability was signiﬁcantly improved, with up to 50% of the isolated
clones stably maintaining GP5fr after 16 passages in tissue culture
(data not shown).
PRRSV minor envelope protein domains expressed by rTGEV
Studies on PRRSV immunobiology have revealed that PRRSV
neutralizing antibodies recognized epitopes within the minor
structural glycoproteins GP2a, GP3 and GP4 (Costers et al., 2010;
Oleksiewicz et al., 2002). rTGEVs were engineered expressing
these proteins, alone or in various combinations, including the
tricistronic expression of GP2a, GP3 and GP4. None of those
proteins was stably expressed by rTGEV vectors, with PRRSV GP3
protein resulting extremely toxic for rTGEV system, leading to
its expression loss in early stages (M. Becares, S. Zuñiga and
L. Enjuanes, unpublished results). The recent identiﬁcation of
antigenic, linear domains in GP3 and GP4 (Costers et al., 2010;
Vanhee et al., 2011) allowed the application of the small domain
expression strategy to these proteins. Fusion domains including
GP3 or GP4 epitopes critical in neutralization, ﬂanked by a few
amino acids (Table 1), and preceded by the corresponding signal
peptide were designed. These peptidic domains consisting of 55
and 50 amino acids of GP3 (GP3fr) and GP4 (GP4fr), respectively,
were fused to the FLAG tag at their C terminus end (Fig. 3A). The
GP3 and GP4 fragments were cloned in TGEV genome in the
location previously occupied by non-essential genes 3a and 3b and
their transcription was driven by the TRS3a. Recombinant viruses
rTGEV-S7.1-TRS3a-GP3fr and rTGEV-S7.1-TRS3a-GP4fr were recov-
ered with titers similar to those of the wt virus. The stability of
the recombinant viruses was analyzed after 8 and 16 passages in
tissue culture, by studying 10 plaque-puriﬁed clones by RT-PCR. All
the clones maintained the heterologous gene sequence, and
Fig. 2. Stability of PRRSV GP5 domains in rTGEV vectors. (A) Schematic representation of PRRSV GP5 constructs: full-length GP5 (GP5), GP5 ectodomain (GP5ecto), and GP5
fragment (GP5fr) that comprises the ectodomain lacking the signal peptide (SP). Immunodominant epitope (IDE) and epitope critical in neutralization (ECN), N-glycosylation
sites (yellow), and the cysteine involved in GP5-M heterodimer formation (red) are also shown. GP5ecto and GP5fr included an HA or FLAG tag, respectively, for their
detection (TG, blue). (B) RT-PCR analysis of ten clones from plaque-puriﬁed passage 8 rTGEV-S7.1-TRS3a-GP5-TRS22N-M (GP5), rTGEV-S7.1-TRS3a-GP5ecto-TRS22N-M (GP5ecto)
and rTGEV-S7.1-TRS3a-GP5fr-TRS22N-M (GP5fr) viruses. The arrow indicates the expected size of the corresponding PCR product. Numbers on the left indicate the molecular
weight markers (Mw) size in base pairs. Lower size bands (indicated by red asterisks) correspond to deletion products from heterologous gene, meaning genomic instability.
Numbers on the right indicate the overall stability of each construct.
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expressed the corresponding mRNA (Fig. 3B), indicating that both
GP3fr and GP4fr were fully stable in the rTGEV vector. Protein
detection using anti-FLAG antibody failed for GP3fr, GP4fr and
GP5fr, both in immunoﬂuorescence and Western blot assays (data
not shown).
Altogether, these data revealed that heterologous gene size
reduction led to a drastic increase in the stability of rTGEV vectors.
PRRSV M protein as scaffold for PRRSV antigenic domains expression
M protein is the most conserved structural protein among PRRSV
strains (Kapur et al., 1996; Murtaugh et al., 1998) and it is the main
inducer of virus-speciﬁc T-cell response (Bautista et al., 1999; Jeong
et al., 2010). Our results indicated that M protein was fully stable in
rTGEV (see above). Therefore, we postulated that M protein could be
used as a scaffold for the expression of small antigenic domains. As a
proof of principle, the GP3 epitope critical in neutralization (ECN)
domain was selected for expression fused to M protein. Two exposed
locations into M protein were predicted using TMpred transmem-
brane topology prediction algorithm (Hofmann and Stoffel, 1993):
the N-terminus and a loop comprising amino acids 63 to 70. GP3
ECN was inserted at these M protein locations, leading to chimeric
structures, GP3ep-NtermM and GP3ep-Mloop, respectively (Fig. 4A).
These chimeric genes were cloned into rTGEV vector, and recombi-
nant viruses rTGEV-S7.1-TRS3a-GP3ep-NtermM and rTGEV-S7.1-TRS3a-
GP3ep-Mloop were rescued with titers similar to those of the
parental virus. The stability of the recovered viruses was analyzed.
After 8 or 16 passages in tissue culture 10 independent clones were
screened by RT-PCR. All the independent clones maintained the
heterologous gene sequence (data not shown) after 8 passages,
whereas after 16 passages 90% and 100% of rTGEV-S7.1-TRS3a-
GP3ep-NtermM and rTGEV-S7.1-TRS3a-GP3ep-Mloop, respectively,
contained the heterologous gene sequence and expressed the
corresponding mRNA (Fig. 4B).
In order to evaluate stability and expression levels of the
chimeric proteins, double immunoﬂuorescence was performed
on cells infected with passage 16 rTGEV-S7.1-TRS3a-GP3ep-NtermM
and rTGEV-S7.1-TRS3a-GP3ep-Mloop viruses. M protein scaffold
was detected in 95% of infected cells in both cases (Fig. 4C). This
detection level was similar to that observed in rTGEV-S7.1-TRS3a-M
expressing full-length wt M protein (see above). In contrast, FLAG
epitope was detected in 92% and 63% of the rTGEV-S7.1-TRS3a-
GP3ep-NtermM and rTGEV-S7.1-TRS3a-GP3ep-Mloop infected cells,
respectively (Fig. 4C). These results strongly suggested that M
protein N-terminus was a more exposed location, and therefore
better to present antigens. This data is in agreement with previous
observations demonstrating that arterivirus M protein is tolerant
to manipulations of its ectodomain (Verheije et al., 2002).
Evaluation of the protective potential of the rTGEVs expressing PRRSV
antigens
In order to evaluate the protection provided by rTGEVs expres-
sing PRRSV antigens, the rTGEVs that showed an increased
Fig. 3. Expression of PRRSV minor envelope protein domains by rTGEV vectors. (A) Schematic representation of PRRSV GP3 and GP4 proteins, and corresponding GP3fr and
GP4fr expressed by rTGEV. Several motifs are indicated, such as signal peptide (SP), the epitope critical in neutralization (ECN), the transmembrane domain (TM), the
glycosylation sites (yellow), and immunodominant epitope (IDE). GP3fr and GP4fr included a FLAG tag (FG) for their detection. (B) RT-PCR analysis of ten clones from plaque-
puriﬁed passage 16 rTGEV-S7.1-TRS3a-GP3fr (GP3fr) and rTGEV-S7.1-TRS3a-GP4fr (GP4fr) viruses. Genomic RNA (gRNA) and GP3fr and GP4fr subgenomic mRNAs (mRNA) were
detected. The arrow indicates the expected size of the corresponding PCR product. Numbers on the left indicate the molecular weight markers (Mw) size in base pairs.
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stability in cell culture were tested in vivo. For that purpose,
rTGEV-S7.1-TRS3a-M, rTGEV-S7.1-TRS3a-GP5fr-M, rTGEV-S7.1-TRS3a-
GP3fr, rTGEV-S7.1-TRS3a-GP4fr, and rTGEV-S7.1-TRS3a-GP3ep-
NtermM were selected for in vivo experiments.
Two groups of twelve days-old piglets were inoculated with
1108 pfu/animal of each rTGEV-S7.1-TRS3a-M, rTGEV-S7.1-TRS3a-
GP5fr-M, rTGEV-S7.1-TRS3a-GP3fr, rTGEV-S7.1-TRS3a-GP4fr, and
rTGEV-S7.1-TRS3a-GP3ep-NtermM (immunized group), or rTGEV
(non-immunized group), respectively, by three routes: oral, nasal
and intragrastic. Previous data from our group indicated that, in
these conditions, the virus in the inoculum reached the target
organs (respiratory and digestive tracts) and replicated to high
titers (Cruz et al., 2011; Sanchez et al., 1999). A boost was
performed 2 weeks after inoculation using the same conditions.
Two weeks later, a challenge was performed with 1106 TCID50 of
PRRSV Olot91-like virulent strain. A control group was inoculated
with 1108 pfu/animal of rTGEV and boosted two weeks later, but
not challenged. Pigs were monitored for clinical signs, focusing on
Fig. 4. PRRSV M protein as an scaffold for antigenic domain expression. (A) Chimeric proteins expressed by rTGEV. Two M protein locations were chosen for the expression of
GP3 epitope involved in neutralization (GP3ECN) fused to a FLAG tag (blue), leading respectively to the chimeras GP3ep-NtermM and GP3ep-Mloop. M protein contains in its
C-terminal an endoplasmic reticulum retention signal (green). (B) RT-PCR analysis of ten clones from plaque-puriﬁed passage 16 rTGEV-S7.1-TRS3a-GP3ep-NtermM (GP3ep-
NtermM) and rTGEV-S7.1-TRS3a-GP3ep-Mloop (GP3ep-Mloop) viruses. Genomic RNA (gRNA) and PRRSV M protein subgenomic mRNA (mRNA) were detected. The arrow
indicates the expected size of the corresponding PCR product. Numbers on the left indicate the molecular weight markers (Mw) size in base pairs. Lower size bands
(indicated by red asterisks) correspond to deletion products from heterologous gene, meaning genomic instability. (C) Immunoﬂuorescence analysis of ST cells infected with
passage 16 rTGEV-S7.1-TRS3a-GP3ep-NtermM (GP3ep-NtermM) and rTGEV-S7.1-TRS3a-GP3ep-Mloop (GP3ep-Mloop) at 8 hpi. TGEV speciﬁc polyclonal antiserum and a
secondary antibody staining red were used to identify infected cells. Expression of chimeric proteins was detected using a monoclonal antibody speciﬁc for PRRSV M protein
(αM) or the FLAG tag (αFLAG) and a secondary antibody staining green.
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respiratory symptoms such as tachypnoea, and abdominal breath-
ing. PRRSV infection resulted in moderate fever, depression and
respiratory signs that persist from days 5 to 25 after challenge
(Fig. 5A). The percentage of animals showing respiratory symp-
toms was signiﬁcantly higher in the non-immunized group than in
the immunized group (Fig. 5A). Moreover, the average weight gain,
which was reduced in challenged animals, was higher in immu-
nized animals than in non-immunized animals between 21 and 28
days post-challenge (data not shown).
Lung damage was analyzed by histopathology of lungs from ﬁve
randomly chosen piglets per group. Lungs from challenged piglets
exhibited features that are characteristic of PRRSV infection such as
pneumocyte hypertrophy and hyperplasia, and intra- alveolar accu-
mulation of cell debris (Fig. 5B, left panels). The lungs from
immunized animals showed a lower degree of lung damage than
those from non-immunized piglets (Fig. 5B, right panel), indicating a
certain degree of protection. The lower extent of lung inﬂammation
observed in immunized animals was in agreement with the lower
levels of proinﬂamatory cytokine IL-8 observed in vaccinated ani-
mals' sera (Fig. 5C). Immunized animals showed a moderate increase
in IL-8 by 3 days post-challenge (31 dpi, as shown in the ﬁgure), but
levels rapidly returned to normal, while non-vaccinated animals
showed a higher elevation of this cytokine, that continued at
elevated levels during the experimental infection. Altogether, these
results suggested that rTGEV vectors expressing PRRSV antigens
conferred partial protection against PRRSV infection.
To further analyze the protection conferred by rTGEVs expres-
sing PRRSV antigens, PRRSV viremia was analyzed by RT-qPCR at
different times post-challenge. Similar virus titers in serum were
obtained in all challenged animals at the initial stages post-
challenge (28–42 dpi) (Fig. 6). Interestingly, a signiﬁcant reduction
in virus titer was observed in the immunized group at 21–28 days
post-challenge (49–56 dpi).
Immune response elicited by rTGEVs expressing PRRVS antigens
In order to evaluate the potential of rTGEVs stably expressing
PRRSV antigens as inducers of immunity against PRRSV, the
humoral response was analyzed at different times post-
inoculation. The antibody response against the TGEV vector, PRRSV
virus and PRRSV individual proteins expressed by rTGEVs were
determined by ELISA. All the animals elicited a high humoral
immune response against TGEV indicating that the vector infected
target tissues as expected, even though the piglets presented pre-
existing anti-TGEV antibodies (data not shown). Seroconversion
against total PRRSV was observed in all challenged animals by day
10 after infection with the virulent virus, while for individual GP3,
GP4 and M protein it was detected by day 14 after challenge. In
all the above-mentioned cases, no differences were observed
between immunized and non-immunized animals (data not
shown). The humoral response against PRRSV N protein followed
identical pattern to that obtained for anti-PRRSV antibodies (data
not shown). These data indicated that anti-PRRSV total antibodies
Fig. 5. Protection conferred by rTGEVs expressing PRRSV antigens. (A) Percentage
of animals showing respiratory symptoms. Observations were made daily during a
time frame of 28 days post-challenge. nn, p-valueo0.05, n, p-valueo0.1. (B) Lung
samples collected at 28 days post-challenge were stained with hematoxylin-eosin.
Representative pictures obtained with a 10x objective are shown (left panels). Lung
damage was scored by observation of 50 random ﬁelds per animal (right panel).
(C) IL-8 levels in serum. Serum samples were collected at the indicated times post-
immunization, mixed in pools of three animals per sample, and cytokine levels
were analyzed by a 7-plex ﬂuorescent microsphere immunoassay. Dots represent
individual samples and solid lines represent mean titer for each group.
n, p-valueo0.1.
Fig. 6. PRRSV titer in serum. PRRSV RNA was isolated from sera at the indicated
times post-immunization, and viremia in serum was quantiﬁed by RT-qPCR. Dots
represent individual animals and solid lines represent mean titer for each group. **,
p-valueo0.05.
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response was most likely directed against N protein and did not
play a role in protection, in agreement with previous reports
showing an early non-neutralizing antibody response obtained
after PRRSV infection (Mateu and Diaz, 2008). Interestingly, a
higher and faster antibody response against GP5 protein was
found from day 42 post-immunization in immunized animals as
compared to the non-immunized ones (Fig. 7A).
The neutralizing antibody response was evaluated in sera from
immunized and non-immunized animals at 14, 21 and 28 days post-
challenge. Non-immunized animals showed higher levels of PRRSV
neutralizing antibodies than the immunized ones (Fig. 7B). This data,
suggested a less effective PRRSV infection in the immunized piglets,
supporting partial protection against PRRSV infection.
Discussion
In this study rTGEV was engineered for the expression of small
protein domains relevant in immune response against PRRSV.
Previous results from our group indicated that instability of certain
heterologous gene expression by rTGEV might represent an
important limitation for its use as an immunogenic vector. The
expression of small protein domains was used as a strategy to
improve heterologous gene stability. Stable expression of protein
antigenic domains contained in highly unstable full-length pro-
teins was achieved. Additionally, as full-length PRRSV M protein
was stably expressed by rTGEV, it was used as a scaffold for the
generation of chimeric proteins that exposed other PRRSV anti-
gens, resulting in highly stable expression. Therefore, size reduc-
tion of the heterologous genes inserted in CoV-derived vectors
resulted in a promising strategy to achieve stable expression.
Protection experiments showed that rTGEV, stably expressing
PRRSV antigenic structures, elicited partial protection against
PRRSV, with a reduction of clinical signs and lung damage in
immunized piglets.
The potential of CoV-derived vectors as systems for gene
delivery has been limited due to its restricted stability. In general,
genetic stability is highly dependent on the nature of the foreign
gene, with some inserts maintained at least twenty passages
whereas others are lost at passage two (de Haan et al., 2005;
Enjuanes et al., 2007; Shen et al., 2009; Sola et al., 2003).
In addition, other factors affect genetic stability of recombinant
CoVs, such as the insert size (de Haan et al., 2005), and the
genomic location in which it is inserted (Bentley et al., 2013).
The maintenance of the inserted genes will also depend on the
recombination rate, conditioned both by the insert size and the
presence in the foreign sequence of regions showing homology
with the virus genome, favoring homologous recombination
(Wang et al., 2003). Furthermore, other heterologous gene or
protein characteristics may affect insert stability, leading to loss
of the inserts harmful for the infected cell or virus replication.
Therefore, it is very difﬁcult to predict the speciﬁc insert stability
in advance, before a highly effort-consuming process to generate
the CoV-derived vectors expressing the heterologous antigen has
been accomplished.
PRRSV GP5 and M genes have similar lengths (606 and 522
nucleotides, respectively) and small ectodomains exposed
between three transmembrane domains. Nevertheless, M protein
was fully stable in rTGEV vectors, while GP5 protein resulted toxic
and its expression was lost after 4–5 passages of the virus in cell
culture. Interestingly, PRRSV hydrophobic M protein resulted
highly toxic in other expression systems, including bacteria and
insect cells (Jeong et al., 2010; Plana-Durán et al., 1997). As
deletion of the heterologous genes could be due to homologous
recombination between the heterologous gene and TGEV genome
because of sequence identity, this possibility was analyzed. No
statistically signiﬁcant sequence identity was identiﬁed between
PRRSV GP5 sequence and TGEV genome. In fact, analysis of the
deletions observed in the unstable recovered viral clones did not
show a common pattern of recombination. In constrast, random
deletions were observed ranging from small deletions affecting
TRS, to larger ones covering most PRRSV GP5 gene sequence (data
not shown), that in all cases led to the loss of protein expression.
Additionally, the GP5 gene, when expressed alone in rTGEV
vectors, was lost at very early passages while it was stably
maintained until passage 8 when it was co-expressed with M
protein, most likely due to the formation of GP5-M heterodimers
(Cruz et al., 2010). These data suggested that the instability was
caused by protein toxicity affecting host cell viability or viral life
cycle, rather than a negative effect of the heterologous gene
sequences on virus genomic stability. This toxicity would confer
selective advantage to those viral clones that did not express GP5
protein.
In this work we showed that size reduction of the foreign insert
signiﬁcantly improved heterologous gene stability. Even in the
Fig. 7. Humoral immune response elicited by rTGEV expressing PRRSV antigens.
(A) Humoral response speciﬁc for GP5. Serum samples were collected at the
indicated times post-immunization and analyzed by ELISA using puriﬁed full-
length GP5. Dots represent individual animals and solid lines represent mean titer
of each group. The arrow indicates the time when challenge was performed.
nnn, p-valueo0.01; nn, p-valueo0.05. (B) Neutralizing antibodies induced at the
indicated times post-challenge. Neutralization assays were performed with PRRSV
Olot91 strain infecting MARC-145 cells. Dots represent individual animals and solid
lines represent mean titer of each group. n, p-valueo0.1.
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case of highly toxic inserts, such as PRRSV GP3 protein, size
reduction led to 100% stability. Therefore, heterologous gene size
reduction is a promising strategy to achieve stable expression in
TGEV-derived vectors and in general in CoVs. This effect could be
due to a decrease of the probability of non-homologous recombi-
nation in shorter sequences, or to the elimination of protein
domains toxically affecting the host cell or rTGEV life cycle. This
result is in agreement with previous studies showing that gene
size affected foreign gene stability in CoV vectors, as the larger
ﬁreﬂy luciferase gene resulted less stable than the shorter Renilla
luciferase gene, when expressed by Feline Infectious Peritonitis
virus (FIPV) vectors (de Haan et al., 2005).
In this paper we used PRRSV M protein, which we have shown
that displays a high stability in rTGEV vectors as a scaffold for the
expression of small antigenic domains. This approach may be
useful to modify the trafﬁcking and accumulation of small protein
domains expressed alone. In fact, protein detection using anti-Flag
antibody failed for GP3fr, GP4fr and GP5fr, both in immunoﬂuor-
escence and Western blot assays (data not shown), probably due
to low accumulation of those peptides inside the cell. Interestingly,
GP3ep-NtermM was detected at high levels, indicating a higher
accumulation in the infected cell of the chimeric protein.
Long-term stability of CoV-derived vectors has not been
systematically addressed. Few proteins have been reported to be
stably expressed by CoVs. Among these, GFP was stable for more
than 6 or 20 passages in tissue culture when expressed by MHV or
TGEV, respectively (Sarma et al., 2002; Sola et al., 2003), but it
showed instability in IBV-derived vectors (Bentley et al., 2013).
PRRSV M protein was also stably expressed by rTGEV for more
than 16 passages (this manuscript). Proteins such as luciferase
expressed by MHV and IBV-derived vectors (Bentley et al., 2013;
de Haan et al., 2005), PRRSV GP5 protein expressed using TGEV
virus vectors (Cruz et al., 2010) or GUS when expressed by TGEV
minigenomes (Alonso et al., 2002b) were lost at early passages. In
our experience, using rTGEV vectors, only around 25% of the
heterologous genes were stably expressed for more than 8 pas-
sages in tissue culture [(Alonso et al., 2002b; Cruz et al., 2010; Sola
et al., 2003), and unpublished results]. This instability is a key
limiting factor in the use of CoV-based vectors for the expression
of full-length proteins.
To improve the stability and efﬁcacy of CoV-derived vectors it
would be essential to understand the factors that control the high
recombination frequency of CoVs. To this end, a detailed analysis
of CoV proteins involved in genetic recombination is needed.
Several enzymes involved in CoV RNA synthesis, such as nsp13
(helicase), nsp15 (endonuclease), nsp14 (exonuclease), nsp7 and
nsp8 (RNA processivity components), or N protein could modulate
recombination in CoVs. The engineering of recombination defec-
tive CoV mutants by knocking-down one or several genes involved
in the recombination process could be the ﬁrst step to achieve
stable expression of large heterologous genes.
In this study, three PRRSV protein domains from GP3, GP4 and
GP5 proteins, recognized by neutralizing antibodies were
expressed by rTGEV and used as immunogens (Costers et al.,
2010; Plagemann, 2004; Vanhee et al., 2011; Wissink et al., 2003),
and the humoral response elicited by these rTGEVs was measured.
After challenge, a faster response against GP5 protein was
observed in immunized piglets. In contrast, the response against
GP3 and GP4 was similar in immunized and non-immunized
piglets. These data suggested that GP5 fragment was immuno-
genic, while GP3 and GP4 domains were antigenic but had a
reduced immunogenicity.
Immunization of piglets with a combination of rTGEV expres-
sing PRRSV antigens led to a clear reduction of clinical symptoms
after challenge, a lower degree of lung damage and a faster viremia
reduction. These results represent an improvement over previous
vaccination experiments using rTGEV vectors expressing PRRSV
antigens (Cruz et al., 2010).
PRRSV correlates of protection remain to be identiﬁed (Kimman
et al., 2009), what represents an additional limitation for the
development of new vaccine candidates. Neutralizing antibodies
seem relevant for preventing PRRSV infection (Lopez and Osorio,
2004), but not enough to provide full protection (Murtaugh and
Genzow, 2011). T-cell responses seem also required in PRRSV
clearance (Mateu and Diaz, 2008). In the present study, immunized
animals showed a signiﬁcant faster recall antibody response against
GP5 protein, which is generally considered the main target of
neutralizing antibodies (Kim and Yoon, 2008; Ostrowski et al.,
2002). Non-immunized animals developed a higher neutralizing
response after challenge with a virulent PRRSV strain, what is
considered as an indication of higher infection, whereas the immu-
nized animals were signiﬁcantly, although partially, protected against
PRRSV infection. With the available data, it is not possible to
determine whether the observed protection was due to an unde-
tectable neutralizing antibody response before challenge [even
commercial available vaccines have been reported to fail in the
induction of detectable levels of neutralizing antibodies before
challenge (Geldhof et al., 2012)] to immune cell responses [most
likely directed to M protein present in the immunization cocktail], or
both. The higher GP5 protein speciﬁc antibody response was
observed from day 10 post-challenge, while signiﬁcant differences
in neutralizing antibodies between immunized and non-immunized
animals were observed between 21 and 28 days post-challenge,
correlating with the differences in viremia, what suggests that the
observed neutralizing response was due to a higher infection of non-
immunized swine. The relative contribution to protection of the
humoral and cellular responses has not been determined. When a
correlation between protection and induction of speciﬁc cytokines
was analyzed, IL-8 levels were signiﬁcantly different between immu-
nized and non-immunized piglets, with levels consistently higher in
non-immunized animals. The exacerbated IL-8 response elicited in
non-immunized animals correlated with the higher lung damage
observed in these animals. This result was in agreement with
previous studies showing that piglets with more severe symptoms,
including viremia and lung lesions, had a continuous elevation of IL-8
in serum, while in animals with milder symptoms IL-8 levels
returned to normal by 7 dpi (Petry et al., 2007). Higher, but not
signiﬁcant, levels of IFN-αwere also observed in immunized animals
compared to non-immunized animals (data not shown), at day 3
post-PRRSV challenge. This result suggested that immunized animals
developed a higher innate immune response, which nevertheless did
not seem strong enough to induce a higher adaptative immune
response.
The construction of rTGEVs expressing small antigenic domains
has considerably improved the stability of the expression vectors.
Nevertheless, some of these small antigens may have limited
immunogenicity. Therefore, the expression of full-length antigens
by engineering CoV vectors with decreased recombination rate
deserves further attention to deﬁnitely launch CoVs as efﬁcacious
vaccine vectors for animal and human health.
Materials and methods
Ethics statement
Experiments involving animals were performed in strict accor-
dance with EU (2010/63/UE) and Spanish (RD 1201/2005 and
32/2007) guidelines. All the protocols were approved by the in
site Ethical Review Committee.
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Cells and viruses
Baby hamster kidney (BHK-21) cells stably transformed with
the gene coding for porcine aminopeptidase N (BHK-pAPN)
(Delmas et al., 1994) were grown in Dulbecco's modiﬁed Eagle's
medium (DMEM) supplemented with 5% fetal calf serum (FCS) and
G418 (1.5 mg/ml) as a selection agent. Recombinant TGEV viruses
obtained in this work were grown in swine testis (ST) cells
(McClurkin and Norman, 1966). Tissue culture adapted PRRSV
Olot91 (GenBank KC862570) strain was grown and titrated in
monkey kidney MARC-145 cells (Kim et al., 1993).
Challenge PRRSV strain
Challenge was performed with a virulent PRRSV strain homo-
logous to PRRSV Olot91 (PRRSV-Olot91-like). PRRSV-Olot91-like
was propagated in porcine macrophages differentiated from fresh
peripheral blood mononuclear cells (PBMCs) as previously
described (Enjuanes et al., 1976). Brieﬂy, 6108 PBMCs isolated
from fresh blood by centrifugation were seeded in 90-mm-
diameter plates in Roswell Park Memorial Institute medium
(RPMI) supplemented with 40% heat-inactivated swine serum.
After 48 h, non-adherent cells where removed and attached
macrophages, that showed 80% of conﬂuence, were infected with
105 TCID50 of the parental PRRSV-Olot91-like. At 72 h post-
infection (hpi), when cytopathic effect was clear, supernatant
was collected and centrifuged. Virus was titrated in porcine
alveolar macrophages (PAMs) as previously described (Duan
et al., 1997).
Plasmid constructs
Fusion products GP3fr, GP4fr, GP5fr GP3ep-Mloop and GP3ep-
NtermM were chemically synthesized and purchased from Gen-
eArt (Germany). The PRRSV Olot91 protein sequences forming the
fusion products are summarized in Table 1.
GP5ecto sequence was ampliﬁed by PCR using the forward primer
(50-GCAGGTCCTATGTACCCCTACGACGTGCCCGACTACGCCATGAGATG-
TTCTCACAAATTGGGGC-30) and the reverse primer (50-GCGCTCAGCT-
CAGGTCTCGACTGCCCAATCAAAATG-30), which included PpuMI and
BlpI restriction sites (underlined), respectively. M sequence was
ampliﬁed using the forward primer (50-GCAGGTCCTATGGGAAGCC-
TAGACGATTTTTG-30) and reverse primer (50-GGGCTAAGCTTACC-
GGCCATACTTGACGAGG-30), which included PpuMI and BlpI restric-
tion sites (underlined), respectively. In both cases, plasmid pSL-
TRS3a-ORF5-TRS22N-ORF6 (Cruz et al., 2010) was used as a template.
PRRSV sequences, both chemically synthesized or PCR ampli-
ﬁed, were digested with restriction endonucleases PpuMI and BlpI
and cloned into the same sites of plasmid pSL-TGEV-S7.1-3ab
including TGEV genomic sequence from nt 22973 to 25873. PRRSV
sequences replaced non-essential genes 3a and 3b, leading to
intermediate plasmids pSL-TRS3a-GP3fr, pSL-TRS3a-GP4fr, pSL-
TRS3a-GP5fr, pSL-TRS3a-GP3ep-Mloop, pSL-TRS3a-GP3fr-NtermM,
pSL-TRS3a-GP5ecto and pSL-TRS3a-M. For the generation of the
dicistronic vectors pSL-TRS3a-GP5ecto-TRS22N-M and pSL-TRS3a-
GP5fr-TRS22N-M, the sequence of M protein preceded by the
optimized synthetic TRS22N (Alonso et al., 2002a) was obtained
from pSL-TRS3a-ORF5-TRS22N-ORF6 by digestion with restriction
endonuclease BlpI and cloned into the same site of pSL-TRS3a-
GP5ecto and pSL-TRS3a-GP5fr.
Finally, all intermediate plasmids containing PRRSV sequences
were digested with AvrII. The resulting fragments were cloned into
the same sites of plasmid pBAC-TGEV-S7.1 (C.M. Sanchez,
M. Becares, S. Zuñiga and L. Enjuanes, unpublished results). This
plasmid was derived from the original pBAC-TGEVFL (Almazan
et al., 2000), containing restriction sites PacI and MluI ﬂanking
S gene (Ortego et al., 2003). Cloning steps led to plasmids pBAC-
S7.1-TRS3a-GP3fr, pBAC-S7.1-TRS3a-GP4fr, pBAC-S7.1-TRS3a-M, pBAC-
S7.1-TRS3a-GP3ep-NtermM, pBAC-S7.1-TRS3a-GP3ep-Mloop, pBAC-
S7.1-TRS3a-GP5ecto-TRS22N-M and pBAC-S7.1-TRS3a-GP5fr-TRS22N-
M. All cloning steps were checked by sequencing of the PCR
fragments and cloning junctions.
Transfection and recovery of infectious rTGEVs from cDNA clones
BHK-pAPN cells were grown to 90% conﬂuence in 35-mm-
diameter plates and transfected with 4 μg of the corresponding
pBAC and 12 μl of Lipofectamine 2000 (Invitrogen), according to
the manufacturer's speciﬁcations. After 6 h of incubation at 37 1C,
cells were trypsinized and plated over a conﬂuent ST monolayer
grown in 35-mm-diameter plate. After a 2-day incubation period,
the cell supernatants were harvested (passage 0). rTGEVs were
cloned by three plaque puriﬁcation steps. rTGEVs were grown and
titrated as previously described (Jimenez et al., 1986).
Analysis of rTGEVs genomic RNA stability
Two clones of each rTGEV were serially passaged, indepen-
dently, in ST cells every 24 h. At passage 8 and 16 ten viral clones
were plaque puriﬁed. RNA from recombinant viruses was puriﬁed
from infected ST cells grown to overconﬂuence on 12-well plates.
Total intracellular RNA was extracted at 18 hpi using the RNeasy
Mini Kit (Qiagen) according to the manufacturer's recommenda-
tions. Reverse transcription was performed with High Capacity
RNA-to-cDNA™ Kit (Life Technologies) according to the manufac-
turer's instructions. PCRs were performed to analyze the size and
sequence of viral genomic RNA (gRNA), at the locus where the
heterologous genes were inserted, and heterologous mRNA size
and sequence synthesis. The primers used and the expected PCR
fragment sizes are shown in Table 2.
Immunoﬂuorescence analysis
Subconﬂuent ST cells grown on glass coverslips were mock
infected or infected at a multiplicity of infection (moi) of 0.5 with
each rTGEV. At 8 hpi cells were washed with phosphate-buffered
saline (PBS), ﬁxed with 4% paraformaldehyde, permeabilized with
0.1% Triton X-100 in PBS and blocked in PBS with 10% FCS.
Monoclonal antibodies speciﬁc for FLAG (FLAG M2, 1:500, Sigma),
PRRSV M protein (EM11E10C7, 1:100, kindly provided by INGE-
NASA), or a polyclonal rabbit serum speciﬁc for TGEV (1:1000)
were used. Bound primary antibody was detected with a Alexa
Fluor 488 or 594-conjugated antibodies speciﬁc for mouse or
rabbit, respectively (1:500, Invitrogen). Cell nuclei were stained
with 40, 6-diamidino-2-phenylindole (DAPI) (1:200, Sigma).
Table 1
Structure of PRRSV fusion proteins expressed by rTGEV. Amino acids in each
segment forming PRRSV fusion proteins.
Fusion proteina Segment 1b Segment 2 Segment 3 Segment 4
GP3fr GP3 (1–28) GP3 (51–77) FLAGc –
GP4fr GP4 (1–25) GP4 (51–75) FLAG –
GP5fr GP5 (35–68) FLAG – –
GP3ep-Mloop M (1–66) GP3 (51–77) FLAG M (67–173)
GP3ep-NtermM FLAG GP3(51–77) M (1–173) –
a PpuMI (AGGTCCT) and BlpI (GCTCGAGC) restriction sites were introduced at
the 50 and 30 ends, respectively. An optimized Kozak sequence (GCCACC) was placed
immediately upstream the ATG start codon to improve protein translation
efﬁciency.
b The numbers in brackets indicate the amino acids included in the con-
struct.
c All constructs included the FLAG tag sequence (amino acids DYKDDDDK).
M. Becares et al. / Virology 464-465 (2014) 274–286 283
Confocal microscopy was performed using a Leica SP5 laser
scanning microscope, and images were collected and processed
with LAS AF software (Leica, Wetzlar, Germany). The percentage of
infected cells expressing PRRSV antigens was estimated by the
analysis of 10 independent microscopy ﬁelds, which represent an
average of more than 400 cells.
Immunization of piglets
Forty-ﬁve twelve days-old non-colostrum-deprived piglets,
born from PRRSV seronegative sows, were inoculated with rTGEV
by three different routes (oral, gastric and intranasal) following
standard procedures (Sanchez et al., 1999). Piglets were divided
into three 15-animal groups. Piglets of group 1 were inoculated
with a mix of 1108 plaque forming units (pfu)/animal of each of
rTGEV-S7.1-TRS3a-GP3fr, rTGEV-S7.1-TRS3a-GP4fr, rTGEV-S7.1-TRS3a-
GP5fr-M, rTGEV-S7.1-TRS3a-M and rTGEV-S7.1-TRS3a-GP3ep-
NtermM. Piglets of groups 2 and 3 were inoculated with
1108 pfu/animal of rTGEV-S7.1. Two weeks after the ﬁrst immu-
nization, all piglets were boosted in the same conditions, and two
weeks later piglets of groups 1 and 2 were challenged with 106
TCID50 of PRRSV-Olot91-like per animal by intranasal route.
Infected animals were monitored daily to detect symptoms of
disease, and body weights were determined every 7 days. Blood
samples were taken at days 0, 14, 28, 31, 35, 38, 42, 49 and 56-
post-ﬁrst inoculation. Five and ten animals per group were
euthanized and necropsied at days 35 and 56, respectively. Lung
macroscopic lesions were evaluated, and lung samples were
collected frozen and in 10% buffered-formalin.
Lung damage measurement
Five piglets per group were randomly chosen for histopatholo-
gical study. Lung representative sections were ﬁxed with 4%
paraformaldehyde and stored in 70% ethanol at 4 1C. Parafﬁn
embedding, sectioning and hematoxylin-eosin staining were per-
formed by the histology service in the National Center of Biotech-
nology (CNB-CSIC, Spain). Samples were examined with a ZEISS
Axiophot ﬂuorescence microscope. Determination of the lung
damage score was obtained from unbiased observation of 50
microscopy ﬁelds per animal, scoring from 0 to 3 attending to
interstitial, peribronchiolar, and perivascular inﬂammation (Page
et al., 2012).
Cytokine level measurement
Quantiﬁcation of porcine IL-1β, IL-10, IFN-α, IFNγ, TNFα, IL-4 and
IL-8 in serum samples was carried out using Swine Cytokine
Magnetic 7-Plex Panel (Life Technologies, TM), and the Luminex
100 IS analyzer, according to the manufacturer's instructions. Three
serum samples, corresponding to the same experimental group and
the same date of extraction, were randomly pooled and analyzed in a
single well. Data were calculated by xPONENT software using a ﬁve-
parameter model derived from the known reference cytokine con-
centrations supplied by the manufacturer. The sensitivity of this
assay allowed the detection of cytokine concentrations with the
following limits of detection: IL-1β (36.808 pg/ml), IL-10 (4.572 pg/
ml), IFN-α (2.661 pg/ml), IFNγ (0.342 pg/ml), TNFα (146.86 pg/ml),
IL-4 (0.548 pg/ml), IL-8 (0.786 pg/ml).
Viremia measurement
Viral RNA was isolated from 250 μl of serum using MagMAX™
Viral RNA Isolation Kit (Life Technologies) according to the
manufacturer's instructions. PRRSV RNA quantity was measured
by RT-qPCR analysis using a custom TaqMan assay detecting
PRRSV N RNA (TaqMan Probe 6-FAM-ACGGCTTTTAATCAAGGC-
MGB; forward primer 50-TTCCCTCTGCTTGCAATCG-30; reverse
primer 50-GGATGAAAGCGACGCAGTTC-30), and the AgPath-ID
one-step RT-PCR kit (Life Technologies) according to the manu-
facturer's instructions. The data were acquired with an ABI Prism
7500 sequence detection system and analyzed with ABI Prism
7000 SDS version 1.2.3 software (Applied Biosystems). Viremia
levels were expressed as the RT-qPCR cycle threshold (Ct) values.
Enzyme-linked immunosorbent assay (ELISA)
Antibodies induced against TGEV and PRRSV viruses or PRRSV
puriﬁed proteins were detected by ELISA as described before
(Sambrook and Russell, 2001). PRRSV GP3, GP4, GP5, M and N
proteins were expressed using the baculovirus-insect cell system.
Recombinant proteins were puriﬁed to near homogeneity by metal
chelate afﬁnity chromatography using Ni-NTA agarose (Sigma-
Aldrich, Madrid, Spain) as previously described (Nogales et al.,
2011). ELISAs were performed using partially puriﬁed TGEV (0.2 μg
per well) and PRRSV (0.05 μg per well) viruses, or PRRSV puriﬁed
proteins GP3 (0.25 μg per well), GP4 (0.5 μg per well), GP5 (0.1 μg
per well), M (0.1 μg per well) and N (0.2 μg per well). Antigens
were bound to 96-well microplates, saturated with 5% bovine
serum albumin (BSA) in PBS for 2 h at 37 1C and incubated with
serial dilutions of the serum sample in Wash Buffer (0.1% BSA,
0.05% Tween20 in PBS) for 90 min at 37 1C. Microplates were
washed three times with Wash Buffer. Bound antibodies were
detected by incubation with peroxidase-conjugated protein A
(BioRad) diluted 1:10000 in PBS with 0.1% BSA. ELISA was devel-
oped with K-Blue TMB substrate (Neogen, Lexington, KY) for 5 min
Table 2
Analysis of rTGEVs stability by RT-PCR. Expected product size and primers used for the analysis of viral gRNA and heterologous mRNA expressed by rTGEVs.
Heterologous gene
Expected size (bp)
gRNAa mRNAb Reverse primer (50-30)
GP3fr 470 301 TTTGTCGTCGTCGTCCTTGTAATC
GP4fr 455 286 TTTGTCGTCGTCGTCCTTGTAATC
GP5 1433 690 GTCCTCGTCAAGGGTTGAGCT
GP5fr-Mc 983 241 TTTGTCGTCGTCGTCCTTGTAATC
GP5ecto-Mc 1082 305 GCGCTCAGCTCAGGTCTCGACTGCCCAATCAAAATG
M 793 637 GGGCTAAGCTTACCGGCCATACTTGACGAGG
GP3fr-Mloop 904 904 GGGCTAAGCTTACCGGCCATACTTGACGAGG
GP3fr-NtermM 904 904 GGGCTAAGCTTACCGGCCATACTTGACGAGG
a PCR for gRNA analysis was performed with the forward primer (50-ATTACGAACCAATTGAAAAAGTGC-30) and the reverse primer (50-CCGCCTGA-
GAAAAGGCTGCATTG-30) in all cases.
b In all cases, forward primer (50-GTGAGTGTAGCGTGGCTATATCTCTTC-30), complementary to the viral leader sequence was used.
c mRNA size shown in the table corresponds to GP5fr or GP5ecto.
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at room temperature. Reactions were stopped with 1.5 M H2SO4,
and the absorbance was read at 450 nm. The ELISA values of the
sera were expressed as sample to positive ratio [SP-ratio¼(OD of
sampleOD of negative control)/(OD of positive controlOD of
negative control)].
Neutralization assay
Serial dilutions of heat-inactivated serum were incubated for
1 h at 37 1C in the presence of 100 pfus of PRRSV-Olot91 in DMEM
containing 5% FCS. The mixtures were added to conﬂuent MARC-
145 cells in 24-well plates. After one hour incubation at 37 1C
medium was removed and 1 ml of DMEM containing 2% FCS and
0.5% agar was added. After 72 h, cells were ﬁxed with 10%
formaldehyde in PBS, stained with a crystal violet solution, and
lysis plaques were counted. A positive control serum, obtained
from a PRRSV infected pig at 56 dpi led to 98–100% of virus
neutralization at a sera dilution of 1:16. In contrast, a non-immune
control serum led to a neutralization of 1 to 5% in the same
experimental conditions. The neutralization index of each serum
sample was expressed relative to the one obtained with the
negative control serum in the experiment [Neutralization
Index¼100%(pfus serum sample/pfus negative control)100].
Statistic analysis
Two-tailed, unpaired Student t tests were used to analyze
difference in mean values between groups. All results were
expressed as means7the standard deviations of the means. Chi-
square test was used to analyze statistical signiﬁcance of differ-
ences in percentages of immunized and non-immunized groups.
p Valueso0.1 were considered signiﬁcant (Noymer, 2008).
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